Opiant Pharmaceuticals (OPNT) Receives Daily Coverage Optimism Score of 0.14

Media coverage about Opiant Pharmaceuticals (NASDAQ:OPNT) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Opiant Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media stories about the technology company an impact score of 45.1070496888511 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Opiant Pharmaceuticals stock traded up $0.22 during mid-day trading on Friday, reaching $14.86. The company’s stock had a trading volume of 23,332 shares, compared to its average volume of 14,618. The company has a market cap of $38.29 million, a P/E ratio of 5.05 and a beta of -0.84. Opiant Pharmaceuticals has a 12 month low of $5.06 and a 12 month high of $51.90.

Get Opiant Pharmaceuticals alerts:

Opiant Pharmaceuticals (NASDAQ:OPNT) last released its earnings results on Tuesday, May 8th. The technology company reported ($3.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($3.39). The business had revenue of $1.70 million during the quarter, compared to the consensus estimate of $2.00 million. Opiant Pharmaceuticals had a negative net margin of 379.64% and a negative return on equity of 574.62%. analysts predict that Opiant Pharmaceuticals will post -5.86 earnings per share for the current fiscal year.

OPNT has been the subject of a number of analyst reports. ValuEngine raised shares of Opiant Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, April 4th. Cantor Fitzgerald initiated coverage on shares of Opiant Pharmaceuticals in a research report on Monday, June 11th. They issued a “buy” rating and a $32.00 target price for the company.

In other news, Director Ann L. Macdougall purchased 5,000 shares of the business’s stock in a transaction on Monday, June 4th. The stock was purchased at an average price of $16.51 per share, for a total transaction of $82,550.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO David D. O’toole purchased 3,000 shares of the business’s stock in a transaction on Friday, May 11th. The stock was purchased at an average price of $18.85 per share, with a total value of $56,550.00. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 10,000 shares of company stock valued at $173,000. Corporate insiders own 63.82% of the company’s stock.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.